Can-Fite BioPharma Ltd. CANF

$ 2.01 0.0%

Annual report 2023
added 11-09-2024

Can-Fite BioPharma Ltd. Balance Sheet 2011-2024 | CANF

Annual Balance Sheet Can-Fite BioPharma Ltd.

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-	-3.5 M	-8.11 M	-16.9 M	-9.27 M	-5.96 M	-1.15 M	-3.84 M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	43 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	1.73 M	2.31 M	3.14 M	2.18 M	2.46 M	1.82 M	2.98 M	3.79 M	5.38 M	1.85 M	37 K	18.2 K	258 K
Total Current Liabilities	2.02 M	2.5 M	2.73 M	1.27 M	3.27 M	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	3.45 M	7.3 M	4.94 M	4.78 M	6.29 M	7.16 M	3.33 M	2.18 M	2.34 M	1.61 M
Deferred Revenue	622 K	783 K	818 K	334 K	469 K	926 K	374 K	322 K	220 K	-	-	-	-
Retained Earnings	-158 M	-151 M	-141 M	-125 M	-110 M	-101 M	-106 M	-91 M	-82.7 M	-78.1 M	-80.5 M	-67.3 M	-60.8 M
Total Assets	9.99 M	9.28 M	20.3 M	9.52 M	8.17 M	7.95 M	7.83 M	10.2 M	17.6 M	10.2 M	6.63 M	1.64 M	4.9 M
Cash and Cash Equivalents	-	-	-	8.27 M	2.7 M	-	-	-	-	-	-	-	-
Book Value	-	-	20.3 M	6.07 M	876 K	3.02 M	3.05 M	3.87 M	10.4 M	6.86 M	4.46 M	-708 K	3.29 M
Total Shareholders Equity	6.24 M	4.47 M	14.4 M	6.07 M	2.44 M	3.02 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Can-Fite BioPharma Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	71 K	-	25 K	-	24 K	-	22 K	-	39 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	3.14 M	-	3.37 M	-	2.18 M	-	2.14 M	-	2.46 M	-	-	-	1.82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	818 K	-	1 M	-	334 K	-	-	-	469 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-141 M	-	-131 M	-	-125 M	-	-119 M	-	-110 M	-	-	-	-97.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	20.3 M	-	9.68 M	-	9.52 M	-	12.8 M	-	8.17 M	-	-	-	7.95 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	4.39 M	-	7.54 M	-	8.27 M	-	9.06 M	-	2.7 M	-	8.2 M	-	3.62 M	-	-	-	3.5 M	-	-	-	8.12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	20.3 M	-	9.68 M	-	9.52 M	-	12.8 M	-	8.17 M	-	-	-	7.95 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	14.4 M	-	3.96 M	-	6.07 M	-	9.16 M	-	2.44 M	-	8.44 M	-	3.02 M	-	-	-	2.98 M	-	-	-	3.91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency